Enhanced endothelialization on surface modified poly(L-lactic acid) substrates.
Improved biodegradable vascular grafts and stents are in demand, particularly for pediatric patients. Poly(L-lactic acid) (PLLA) is an FDA-approved biodegradable polymer of potential use for such applications. However, tissue culture studies have shown that endothelial cell (EC) attachment and growth occurs relatively slowly on PLLA surfaces. This slow growth has been attributed to the fact that PLLA represents a hydrophobic substrate, relatively devoid of active functional groups. As a result, the slow EC recovery on the luminal side of PLLA stents provides an increased risk of induced thrombosis. In the present study, surface modification of PLLA substrates has been examined as a potential route to enhance EC growth. For this purpose, PLLA surfaces were modified via pulsed plasma deposition of thin films of poly(vinylacetic acid). The -COOH surface groups, introduced by the plasma deposition, were employed to conjugate fibronectin (FN), followed by attachment of vascular endothelial growth factor to FN. Pig Aorta ECs (PAE) and kinase-insert domain-containing receptor (KDR)-transfected PAE showed increased cell adhesion and proliferation, as well as substantially improved cell retention under fluidic shear stress on surface-modified PLLA compared with untreated PLLA. Although KDR-transfected PAE exhibited better cell proliferation than PAE, normal EC functions, including EC morphology, nitric oxide production, and KDR expression, were observed when cells were grown on surface-modified PLLA. The results obtained clearly indicate that this combined surface modification technique using poly(vinylacetic acid) deposition, FN conjugation, and vascular endothelial growth factor surface delivery can enhance endothelialization on PLLA, particularly when employed in conjunction with the growth of KDR-transfected ECs.
Xu
Hao
H
Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Deshmukh
Rajendrasing
R
Timmons
Richard
R
Nguyen
Kytai Truong
KT
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D004727:Endothelium / Q000187:drug effects* / Q000378:metabolism*; D005353:Fibronectins / Q000494:pharmacology; D005453:Fluorescence; D005455:Fluorescent Antibody Technique; D006801:Humans; D032389:Myocytes, Smooth Muscle / Q000166:cytology; D009569:Nitric Oxide / Q000378:metabolism; D056951:Photoelectron Spectroscopy; D011091:Polyesters / Q000494:pharmacology*; D012212:Rheology / Q000187:drug effects; D017550:Spectroscopy, Fourier Transform Infrared; D013314:Stress, Mechanical; D013499:Surface Properties / Q000187:drug effects; D034421:Sus scrofa; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism
D005353:Fibronectins; D011091:Polyesters; D042461:Vascular Endothelial Growth Factor A; D009569:Nitric Oxide; C033616:poly(lactide); D040301:Vascular Endothelial Growth Factor Receptor-2